Steatosis as a risk factor in liver surgery

Annals of Surgery

Volumn 245, Issue 1, 2007, Pages 20-30

  Veteläinen, Reeta ^a   Van Vliet, Arlène ^a   Gouma, Dirk J ^a   Van Gulik, Thomas M ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DIDANOSINE; ESTROGEN; FIALURIDINE; GLUCOCORTICOID; GLUCOSE; INSULIN; METHOTREXATE; PETROLEUM; PHOSPHORUS; TAMOXIFEN; TETRACYCLINE; VALPROIC ACID; WARFARIN;

ABETALIPOPROTEINEMIA; BODY FAT DISTRIBUTION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENTERITIS; FATTY LIVER; GALACTOSEMIA; GASTROINTESTINAL SURGERY; GLUCOSE HOMEOSTASIS; HEPATITIS C; HISTOPATHOLOGY; HOMOCYSTINURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERLIPIDEMIA; INBORN ERROR OF METABOLISM; INFORMATION RETRIEVAL; INSULIN RESISTANCE; LIVER HISTOLOGY; LIVER ISCHEMIA; LIVER REGENERATION; LIVER SURGERY; LIVER TRANSPLANTATION; LIVING DONOR; MEDICAL LITERATURE; MEDLINE; NEEDLE BIOPSY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN MALNUTRITION; REPERFUSION INJURY; REVIEW; RISK FACTOR; SURGICAL RISK; TISSUE SECTION; TOTAL PARENTERAL NUTRITION; TYROSINEMIA; UREA CYCLE; WEIGHT REDUCTION;

FATTY LIVER; HEPATECTOMY; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33845922813     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000225113.88433.cf     Document Type: Review

References (135)

1. Redaelli CA, Wagner M, Krahenbuhl L, et al. Liver surgery in the era of tissue-preserving resections: early and late outcome in patients with primary and secondary hepatic tumors. World J Surg. 2002;26:1126-1132.
2. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97-106.
3. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis. 2001;21:105-113.
4. Wu CC, Ho WL, Yeh DC, et al. Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery. 1998;123:270-277.
5. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 1994;20:829-838.
6. Trevisani F, Colantoni A, Caraceni P, et al. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol. 1996; 22:114-121.
7. Markin RS, Wisecarver JL, Radio SJ, et al. Frozen section evaluation of donor livers before transplantation. Transplantation. 1993;56:1403-1409.
8. Adam R, Reynes M, Johann M, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc. 1991;23:1538-1540.
9. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation: a multivariate analysis. Transplantation. 1993;55:8087-8013.
10. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:292-298.
11. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
12. Crowley H, Lewis WD, Gordon F, et al. Steatosis in donor and transplant liver biopsies. Hum Pathol. 2000;31:1209-1213.
13. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis. 2001;21:105-113.
14. Imber CJ, St. Peter SD, Handa A, et al. Hepatic steatosis and its relationship to transplantation. Liver Transpl. 2002;8:415-423.
15. Sauer P, Schemmer P, Uhl W, et al. Living-donor liver transplantation: evaluation of donor and recipient. Nephrol Dial Transplant. 2004;19: 11-15.
16. Burt AD, MacSween RNM, Peters TJ, et al. Nonalcoholic Fatty Liver: Causes and Complications. Oxford: Oxford University Press, 863-872.
17. Sherlock S. Acute fatty liver of pregnancy and the microvesicular fat diseases. Gut. 1983;24:260-269.
18. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002;8: 1221-1231.
19. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaplatin pretreatment on respectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-853.
20. Saksena S. Natural history and determinants of disease progression in non-alcoholic fatty liver disease: good and bad news. Hepatology 2003;38:233A.
21. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000; 132:112-117.
22. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988;27:142-149.
23. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight lost after gastroplasty. Int J Obes. 1998;22:222-226.
24. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85:1349-1355.
25. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428-1432.
26. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci. 2002;40:2002-2009.
27. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
28. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12: 1106-1110.
29. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719.
30. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
31. Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40:1805-1815.
32. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology 2001;120(suppl A).
33. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1980;126:137-145.
34. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics: a clinical and histologic comparison with alcohol-induced liver disease. Gastroenterology. 1988;95:1056-1062.
35. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30:1356-1362.
36. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001;7:409-414.
37. Kral J, Schaffner F, Pierson R, et al. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548-551.
38. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906.
39. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396-1400.
40. Brunt EM, Janney CG, Di Biseglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
41. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171-180.
42. Markin RS, Wisecarver JL, Radio SJ, et al. Frozen section evaluation of donor livers before transplantation. Transplantation. 1993;56:1403-1409.
43. Urena MA, Ruiz-Delgado FC, Gonzalez EM, et al. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg. 1998;22:837-844.
44. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725.
45. Nomura F, Ohnishi K, Ochiai T, et al. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low calorie diet. Radiology. 1987;27:108-113.
46. Mitchell DG. Focal manifestations of diffuse liver disease at MR imaging. Radiology. 1992;185:10-11.
47. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123:745-750.
48. Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467-471.
49. Finch MD, Crosbie JL, Currie E, et al. An 8-year experience of hepatic resection: indications and outcome. Br J Surg. 1998;85:315-319.
50. Iwatsuki S, Starzl TE. Personal experience with 411 hepatic resections. Ann Surg. 1988;208:421-434.
51. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138:1198-1206.
52. Kubota K, Makuuchi M, Sugawara Y, et al. Reconstruction of the hepatic and portal veins using a patch graft from the right ovarian vein. Am J Surg. 1998;176:295-297.
53. Little SA, Jarnagin WR, DeMatteo RP, et al. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg. 2002;6:88-94.
54. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-407.
55. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034-1044.
56. Broelsch CE, Burdeleski M, Rogiers X, et al. Living donor for liver transplantation. Hepatology. 1994;20:49.
57. Miller CM, Gondolesi GE, Florman S, et al. One hundred nine living donor liver transplants in adults and children: a single center experience. Ann Surg. 2001;3:301-312.
58. Bak T, Wachs M, Trotter J, et al. Adult-to-adult living donor liver transplantation using right-lobe-grafts: results and lessons learned from a single center experience. Liver Transplant. 2001;7:680-686.
59. American Society of Transplant Surgeons Ethics Committee. Position paper on living-donor transplant. Liver Transplant. 2000;6:815.
60. Soejima Y, Shimada M, Suehiro T. Use of steatotic graft in living-donor liver transplantation. Transplantation. 2003;76:344-348.
61. Hayashi M, Fujii T, Kiuchi K, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. Transplant Proc. 1999;31:403.
62. Ito T, Kiuchi T, Egawa H, et al. Surgery-related morbidity in living donors of right-lobe liver graft: lessons from the first 200 cases. Transplantation. 2003;76:158-163.
63. Yoong KF, Gunson BK, Neil DAH, et al. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. Transplant Proc. 1999;31:550-551.
64. Shimada M, Matsumata T, Akazawa K, et al. Estimation of risk of major complications after hepatic resection. Am J Surg. 1994;164:399-403.
65. Poon R, Sheung-Tat Fan MS, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol. 2002;97:1480-1488.
66. Cruse RJ, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg. 1973;107:206-210.
67. Dindo D, Muller MK, Weber M, et al. Obesity in general elective surgery. Lancet. 2003;361:2032-2035.
68. Tsukada K, Miyazaki T, Kato H, et al. Body fat accumulation and postoperative complications after abdominal surgery. Am Surg. 2004;70:347-351.
69. Fong D, Nehra V, Lindor K, et al. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 2000;32:3-10.
70. Fisher R. Hepatobiliary abnormalities associated with total parenteral nutrition. Gastroenterol Clin North Am. 1989;18:645-666.
71. McGarry J, Foster D. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395-420.
72. Day C, James O. Hepatic steatosis: innocent bystander or guilty party? Hepatology. 1998;27:1463-1466.
73. Pessayre D, Berson A, Fromety B, et al. Mitochondria in steatohepatitis. Semin Liver Dis. 2001;21:57-69.
74. Yang S, Zhu H, Lane M, et al. Obesity increases sensitivity to endotoxin liver injury; implication for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA. 1997;94:2557-2562.
75. Neushwander-Tetri BA, Caldwell AH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219.
76. Fan C-Y, Pan J, Usuda N, et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisomal proliferator activated receptor alpha natural ligand metabolism. J Biol Chem 1998;273:15639-15645.
77. Weltman M, Farrell G, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;111:1645-1653.
78. Leclerq I, Farrell G, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxidation in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075.
79. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136:727-733.
80. Yang S, Zhu H, Li H, et al. Mitochondrial adaptations to obesity-related oxidative stress. Arch Biochem Biophys. 2000;378:259-268.
81. Rashid A, Wu TC, Huang C, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. 1999;29:1131-1138.
82. Reddy JK, Goel SK, Nemali MR, et al. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisomal proliferators. Proc Natl Acad Sci USA. 1986;83:1747-1752.
83. Marchesini G, Brizi M, Morselli-Labate AM, et al. Metformin in nonalcoholic steatohepatitis. Lancet. 2001;358:893-894.
84. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40:47-51.
85. Marcos A, Fisher R, Ham JM, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation. 2000;69:1375-1379.
86. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts: an overview and synthesis of current studies. Transplantation. 1992;53:957-978.
87. Huguet C, Gavelli A, Chieco PA, et al. Liver ischemia for hepatic resection: where is the limit? Surgery. 1992;111:251-259.
88. Caldwell-Kinkel JC, Currin RT, Tanaka Y, et al. Reperfusion injury to endothelial cells following cold storage of rat liver. Hepatology. 1989;10:292-299.
89. Jaeschke H. Mechanism of reperfusion injury after warm ischemia of the liver. J Hepatobiliary Pancreat Surg. 1998;21:402-408.
90. Lemasters JJ. The mitochondrial permeability transition and the calcium, oxygen and pH paradoxes: one paradox after another. Cardiovasc Res. 1999;44:470-473.
91. Pannen BH, Al-Adili F, Bauer M, et al. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology. 1998;27:755-764.
92. Sun CK, Zhang XY, Zimmermann A, et al. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of Zucker rat. Transplantation. 2001;72:1625-1631.
93. Seifalian AM, Piasecki C, Agarwal A, et al. The effect of graded steatosis on the flow in the hepatic parenchymal microcirculation. Transplantation. 1997;68:780-784.
94. Sato N, Eguchi H, Inoue A, et al. Hepatic microcirculation in Zucker fatty rats. Adv Exp Med Biol. 1986;200:477-483.
95. Teramoto K, Bowers JL, Kruskal JB, et al. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation. 1993;56:1076-1082.
96. Hayashi M, Tokunaga Y, Fujita T, et al. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation. 1993;56:282-296.
97. McCuskey RS, Ito Y, Robertson GR, et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004;40:386-393.
98. Selzner M, Rudiger HA, Sindram D, et al. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology. 2000;32:1280-1288.
99. Hakamada K, Sasaki M, Takahashi K, et al. Sinusoidal flow block after warm ischemia in rat fed diet-induced fatty liver. J Surg Res. 1997;70:12-20.
100. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995;108:252-275.
101. Domenicali M, Vendemiale G, Serviddio G, et al. Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. Dig Liver Dis. 2005;37:689-697.
102. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282:1659-1664.
103. Chavin K, Yang S, Lin H, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999;274:5692-5700.
104. Fukumori T, Ohkochi N, Tsukamoto S, et al. Why fatty liver is unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc. 1997;29:412-415.
105. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1196.
106. McCuskey RS, Ito Y, Robertson GR, et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004;40:386-393.
107. Wanner GA, Ertel W, Muller P, et al. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock. 1996;5:34-40.
108. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation. 2002;74:7-13.
109. Yadav SS, Howell DN, Steeber DA, et al. P-selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology. 1999;29:1494-1502.
110. Nakano H, Nagasaki H, Barama A, et al. The effects of n-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the steatotic liver produced by a choline-methionine-deficient diet. Hepatology. 1997;26:670-678.
111. Hakamada K, Sasaki M, Takahashi K, et al. Sinusoidal flow block after warm ischemia in rats with diet-induced fatty liver. J Surg Res. 1997;70:12-20.
112. Yang S, Lin HZ, Mandal AK, et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology. 2003;34:694-706.
113. Torbenson M, Yang SQ, Liu HZ, et al. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol. 2002;161:155-161.
114. Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol. 2001;281:G382-G392.
115. Taub R, Greenbaum LE, Peng Y. Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin Liver Dis. 1999;19:117-127.
116. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379-1383.
117. Selzner M, Clavien PA. Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology. 2000;31:35-42.
118. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
119. Ihle JN. Cytokine receptor signaling. Nature. 1995;377:591-594.
120. Cressman DE, Diamond RH, Taub R. Rapid activation of the Stat3 transcription complex in liver regeneration. Hepatology. 1995;21:1443-1449.
121. Lee DG, Bell SP. ATPase switches controlling DNA replication initiation. Curr Opin Cell Biol. 2000;12:280-285.
122. Vendemiale G, Grattagliano I, Caraceni P, et al. Mitochondrial oxidative injury and energy metabolism alteration in fatty liver: effect of nutritional status. Hepatology. 2001;33:808-815.
123. Eguchi Y, Shimazu S, Tsujimoto Y. Intracellular ATP levels determine cell death by apoptosis and necrosis. Cancer Res. 1997;57:1835-1840.
124. Leclercq IA, Field J, Farrell GC. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology. 2003;124:1451-1464.
125. Green RM. NASH: hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14-17.
126. Yamagami K, Enders G, Schauer RJ, et al. Heat-shock preconditioning protects fatty livers in genetically obese Zucker rats from microvascular perfusion failure after ischemia reperfusion. Transpl Int. 2003;16:456-463.
127. Choi S, Noh J, Hirose R, et al. Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats. Ann Surg. 2005;241:470-476.
128. Peralta C, Hotter G, Closa D, et al. Protective effect of ischemic preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: role of nitric oxide and adenosine. Hepatology. 1997;25:934-937.
129. Serafin A, Rosello-Catafau J, Prats N, et al. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol. 2002;161:587-601.
130. Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem. 2004;4:23916-23924.
131. Schemmer P, Schoonhoven R, Swenberg JA, et al. Gentle organ manipulation during harvest as a key determinant of survival of fatty livers after transplantation in the rat. Transplant Int. 1999;12:351-359.
132. Takahashi K, Hakamada K, Totsuka E, et al. Warm ischemia and reperfusion injury in diet-induced canine fatty livers. Transplantation. 2000;27:2028-2034.
133. Spannbauer MM, Oleszczuk A, Tannapfel A, et al. Micro- and macrovesicular steatotic liver model for transplantation induced by ethanol and protein-deficient diet. Transplant Proc. 2005;1:210-211.
134. Yin W, Liao D, Kusunoki M, et al. NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine. J Endocrinol. 2004;180:399-408.
135. Clavien PA, Selzner M, Rudiger HA, et al. A prospective, randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg. 2003;238:845-852.